One of every six clinical trials that is carried out in Spain is already to investigate orphan drugs

Source: farmaindustria.es The commitment of the pharmaceutical industry to the research and development of treatments for rare diseases is indisputable and, as the data show, growing. About 16% of the clinical trials (15.8%) promoted by pharmaceutical companies in Spain between 2015 and the first half of 2018 (one in six) already correspond to medicines designated […]

Spain attracts more than 250 clinical trials in oncohematology in the last four years

Source: Farmaindustria.es Various facts and arguments support the condition of Spain as an attractive country for the development of biopharmaceutical research projects: the quality of its health system, the prestige and recognition of its researchers, a highly advanced scientific and logistical infrastructure, the active commitment of patients , the experience and capacity of its pharmaceutical […]

Develop new medicines, make them accessible in a sustainable environment and attract investments to the country, objectives of the pharmaceutical industry in Spain

Source: Farmaindustria.es Investigate and develop new medicines more and more precise and effective, facilitate the access of patients to these innovative drugs in an environment of sustainability of the health system and to attract the country the maximum possible investment in biomedical R & D are the three main objectives of the pharmaceutical industry based […]

The Carlos III Health Institute announces new European calls for research

Source: actasanitaria.com The Health Institute Carlos III (ISCIII) has announced that, through European programs, has “about five million euros” to participate in the latest calls open by the European Union (EU) to finance various projects of research, among which are those related to Personalized Medicine. To this ISCIII funding are added “around three million euros […]

AEMPS corrects its document on instructions for clinical trials in Spain

Source: actasanitaria.com The Spanish Agency for Medicines and Healthcare Products (AEMPS) has published the correction of errors of version 10 of the document of instructions for conducting clinical trials in Spain, which came out on December 17, 2018. The Royal Decree 1090/2015, of December 4, which regulates clinical trials with drugs, the Research Ethics Committees […]

A new refinement increases the safety of CAR-T therapy

Source: Immedicohospitalario.es Bellicum Pharma has reported the preliminary results of its phase I / II dose escalation study in 12 patients with metastatic pancreatic cancer treated with BPX-601, the first CAR-T therapy with a controllable activation mechanism. Of the 6 patients evaluable so far, four had stabilization of the disease, with the reduction in tumor […]

Investigations of the Carlos III National Center for Cardiovascular Research

Source: Immedicohospitalario.es The studies published by the CNIC scientists during the year 2017 consolidate this center as an institution of Spanish and international research excellence, highlighting mainly the work on cardiovascular diseases, immunity, cancer, metabolism and pharmacological toxicity. Analysis of gene function The team of Dr. Rui Benedito has developed a new technology that allows […]

New method for the prediction of response to treatment in clinical trials

Source: immedicohospitalario.es Researchers from the universities of Vienna and Lancaster have developed a method aimed at improving precision medicine already during the clinical development phase of the drug. Based on the statistical processing of data related to biomarkers obtained by genomic sequencing and molecular imaging, it enables the identification of patients who will respond better […]

Combining metformin and an antihypertensive is effective against tumors

Source: redaccionmedica.com A common medication for diabetes, combined with a drug against high blood pressure, is able to inhibit the growth of tumorese induce the death of cancer cells by turning off their energy supply, researchers have revealed Biozentrum of the University of Basel (Switzerland). In a follow-up study published in the journal Cell Reports, […]

Advances in therapies directed to lymphocytes in systemic lupus erythematosus

Source: immedicohospitalario.es Systemic lupus erythematosus (SLE) is an autoimmune disease with multifaceted and extremely variable clinical manifestations, characterized by relapses and outbreaks followed by periods of remission. Until recently, the management of the disease has been based on non-steroidal anti-inflammatories, glucocorticoids, immunosuppressants and hydroxychloroquine. Although these agents have improved the prognosis of SLE, they still […]